• Search Icon Search

    Search

    Search Icon
  • Share Icon Share

    Share

    • Facebook
    • Twitter
    • LinkedIn
    • Mail
    Share Icon
  • Location Icon Location

    Location

    North America
    Europe
    Asia
    Idorsia is expanding its global footprint to reach more patients with our transformative treatments.
    We conduct research, clinical development and commercial operations out of the following locations. Click the pin to find out more.     Click the arrows to navigate across geographies.
    Click the pin to find out more.

    Idorsia Pharmaceuticals Ltd

    Hegenheimermattweg 91
    4123 Allschwil
    Switzerland

    Idorsia Pharmaceuticals Ltd

    Hegenheimermattweg 91
    4123 Allschwil
    Switzerland
    Headquarters of Idorsia Ltd.
    Responsible for drug discovery, development, registration, production, quality assurance, safety, as well as company management and coordination.
    • www.idorsia.com
    • Contact us online

    Idorsia (Berlin) Pharmaceuticals GmbH

    Magnusstrasse 11
    D-12489 Berlin
    Germany
    A 100% subsidiary of Idorsia Pharmaceuticals Ltd, based in Berlin, Germany
    – discovers and develops synthetic carbohydrate vaccines to prevent infection.

    Idorsia Clinical Development US Inc.

    1820 Chapel Avenue West Suite
    150 Cherry Hill, NJ 08002
    United States
    Based in New Jersey, US
    – performs clinical development on behalf of Idorsia.

    Idorsia Pharmaceuticals Deutschland GmbH

    Marie-Curie-Strasse 8
    DE-79539 Lörrach
    Germany
    A 100% subsidiary of Idorsia Ltd, based in Lörrach, Germany
    – performs clinical development on behalf of the Group and acts as Idorsia’s representative for obtaining regulatory approvals in the EU.

    Idorsia Pharmaceuticals UK Limited

    20 Eastbourne Terrace London,
    W2 6LG
    United Kingdom
    A 100% subsidiary of Idorsia Ltd, based in London, United Kingdom
    – is responsible for the Group’s marketing operations in the United Kingdom.

    Idorsia Pharmaceuticals Spain S.L.

    Paseo Castellana 79
    ES-28046 Madrid
    Spain
    A 100% subsidiary of Idorsia Ltd, based in Madrid, Spain
    – is responsible for the Group’s marketing in Spain.

    Idorsia Pharmaceuticals Canada Ltd.

    220-6500 RTE Transcanadienne
    Pointe Claire, Quebec
    H9R0A5
    Canada
    Based in Montreal, Canada
    – responsible for the Idorsia’s commercial operations in Canada.

    Idorsia Pharmaceuticals Germany GmbH

    Dachauerstr. 63
    80335 München
    Germany
    A 100% subsidiary of Idorsia Ltd, based in Munich, Germany
    – is responsible for the Group’s marketing operations in Germany.

    Idorsia Pharmaceuticals France SAS

    Immeuble Colisée Gardens -
    Bâtiment B
    8-14 Avenue de l'Arche
    FR-92400 Courbevoie
    France
    A 100% subsidiary of Idorsia Ltd, based in Paris, France
    – will be responsible for the Group’s marketing operations in France.

    Idorsia Pharmaceuticals US Inc.

    One Radnor Corporate Center, Suite 101
    100 Matsonford Rd
    Radnor, PA 19087
    United States
    Based in Radnor, Pennsylvania, US
    – is responsible for the commercial operations in the US.

    Idorsia Pharmaceuticals Nordics AB

    c/o FirstOffice
    Gustav III's Boulevard 46
    169 73 Solna
    Sweden
    A 100% subsidiary of Idorsia Ltd, based in Stockholm, Sweden
    – responsible for the Idorsia’s commercial operations in Sweden, Norway, Finland, and Denmark.

    Idorsia Pharmaceuticals Italy S.r.l.

    Via Fabio Filzi 25A
    20124 Milan
    Italy

    Idorsia (Shanghai) Pharmaceuticals Co., Ltd

    Room 311, No. 6, Lane 368
    Lushuo Road
    Shanghai
    China
    Based in Shanghai, PRC
    – performs research and development on behalf of Idorsia.
    Location Icon
  • Contact Icon Contact

    Contact

    General Contact:

    Idorsia Pharmaceuticals Ltd
    Hegenheimermattweg 91
    4123 Allschwil
    Switzerland

    +41 58 844 00 00

    Please get in touch with us via the contact form by clicking "Next".

    Whistleblower hotline:

    • Switzerland: 0800 110 007
    • USA: (833) 222-3891 (anonymous reporting channel)
    • Outside Switzerland and USA: +41 58 844 0106

    Learn more about our Governance by clicking "Next"

    Data Protection Officer:

    Idorsia attempts to ensure that your Personal Data are updated, accurate, and complete according to the information that has been provided. Any request related to the exercise of your privacy rights can be sent through the link below. 

    Stay informed:

    To best serve your interest, Idorsia offers an electronic ‘Stay Informed’ service. With this service you have the possibility to automatically receive Idorsia's Media Releases directly to your inbox. In addition, if you provide your mobile phone number, we will send you an alert via SMS when the media release is published.

    Contact Icon
  • Home
  • About Idorsia
      Overview
    • Our strategic priorities
    • Our People
    • Partnerships
    • How we started
  • Our Innovation
      Overview
    • Bench to bedside
    • Portfolio
      • Portfolio overview
      • Daridorexant
      • Aprocitentan
      • Lucerastat
    • Target Diseases
      • Insomnia
      • Systemic hypertension
      • Fabry disease
    • Serving patients
  • Sustainability
      Overview
    • Our approach
    • Advancing science and healthcare
    • People and society
    • Environment
    • Compliance and business ethics
    • Reporting
  • Investors
      Overview
    • Results day center
    • Equity story
    • Financial information
    • Corporate reports
    • News and events
      • Media releases
      • Investor webcasts
      • Annual General Meeting
    • Stock information
      • Stock overview
      • Stock chart tools
    • Governance
  • Media
      Overview
    • News
      • News Archive
    • Media center
    • Social media
  • Careers
      Overview
    • Working at Idorsia
    • Job opportunities
    • Living in Basel
    • FAQ

This website is subject to the terms and conditions outlined in the legal and privacy statement.

Terms and conditions Privacy Policy Data Notice Site map

Copyright © 2025 Idorsia Pharmaceuticals Ltd